Tumor associated antigen PRAME is a marker of favorable prognosis in childhood acute myeloid leukemia patients and modifies the expression of S100A4, Hsp 27, p21, IL-8 and IGFBP-2 in vitro and in vivo

References

• Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005; 54: 187–207
   PubMed Web of Science ®Google Scholar
• Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain J F, de Smet C, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997; 6: 199–208
   PubMed Web of Science ®Google Scholar
• van Baren N, Chambost H, Ferrant A, Michaux L, Ikeda H, Millard I, et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol 1998; 102: 1376–1379
   PubMed Web of Science ®Google Scholar
• Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res 2004; 10: 4307–4313
   PubMed Web of Science ®Google Scholar
• Epping M T, Wang L, Edel M J, Carlee L, Hernandez M, Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 2005; 122: 835–847
   PubMed Web of Science ®Google Scholar
• Tajeddine N, Gala J L, Louis M, Van Schoor M, Tombal B, Gailly P. Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo. Cancer Res 2005; 65: 7348–7355
   PubMed Web of Science ®Google Scholar
• de Greef G E, van Putten W L, Boogaerts M, Huijgens P C, Verdonck L F, Vellenga E, et al. Criteria for defining a CR in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies. Br J Haematol 2005; 128: 184–191
   PubMed Web of Science ®Google Scholar
• Aladjidi N, Auvrignon A, Leblanc T, Perel Y, Benard A, Bordigoni P, et al. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. J Clin Oncol 2003; 21: 4377–4385
   PubMed Web of Science ®Google Scholar
• Steinbach D, Hermann J, Viehmann S, Zintl F, Gruhn B. Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet Cytogenet 2002; 133: 118–123
   PubMed Web of Science ®Google Scholar
• Tajeddine N, Millard I, Gailly P, Gala J L. Real-time RT-PCR quantification of PRAME gene expression for monitoring minimal residual disease in acute myeloblastic leukaemia. Clin Chem Lab Med 2006; 44: 548–555
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322–2333
   PubMed Web of Science ®Google Scholar
• Greiner J, Schmitt M, Li L, Giannopoulos K, Bosch K, Schmitt A, et al. Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. Blood 2006; 108: 4109–4117
   PubMed Web of Science ®Google Scholar
• Steinbach D, Schramm A, Eggert A, Onda M, Dawczynski K, Rump A, et al. Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia. Clin Cancer Res 2006; 12: 2434–2441
   PubMed Web of Science ®Google Scholar
• Matsushita M, Ikeda H, Kizaki M, Okamoto S, Ogasawara M, Ikeda Y, et al. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. Br J Haematol 2001; 112: 916–926
   PubMed Web of Science ®Google Scholar
• Zhou P Y, Li W J, Wei C X, Zhou Z. Expression of PRAME gene in adult acute leukemia and its significance in prognosis. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2007; 15: 1177–1181
   PubMedGoogle Scholar
• Paydas S, Tanriverdi K, Yavuz S, Disel U, Baslamisli F, Burgut R. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects. Am J Hematol 2005; 79: 257–261
   PubMed Web of Science ®Google Scholar
• Spanaki A, Perdikogianni C, Linardakis E, Kalmanti M. Quantitative assessment of PRAME expression in diagnosis of childhood acute leukemia. Leuk Res 2007; 31: 639–642
   PubMed Web of Science ®Google Scholar
• Mazzucchelli L. Protein S100A4: too long overlooked by pathologists?. Am J Pathol 2002; 160: 7–13
   PubMed Web of Science ®Google Scholar
• Kasimir-Bauer S, Ottinger H, Meusers P, Beelen D W, Brittinger G, Seeber S, et al. In acute myeloid leukemia, coexpression of at least two proteins, including P-glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat-shock protein 27, is predictive of the response to induction chemotherapy. Exp Hematol 1998; 26: 1111–1117
   PubMed Web of Science ®Google Scholar
• Garrido C, Schmitt E, Cande C, Vahsen N, Parcellier A, Kroemer G. HSP27 and HSP70: potentially oncogenic apoptosis inhibitors. Cell Cycle 2003; 2: 579–584
   PubMed Web of Science ®Google Scholar
• Gartel A L, Tyner A L. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002; 1: 639–649
   PubMed Web of Science ®Google Scholar
• Gartel A L, Radhakrishnan S K. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 2005; 65: 3980–3985
   PubMed Web of Science ®Google Scholar
• Gartel A L. The conflicting roles of the cdk inhibitor p21(CIP1/WAF1) in apoptosis. Leuk Res 2005; 29: 1237–1238
   PubMed Web of Science ®Google Scholar
• Munker R, Zhang W, Elstner E, Koeffler H P. Vitamin D analogs, leukemia and WAF1. Leuk Lymphoma 1998; 31: 279–284
   PubMed Web of Science ®Google Scholar
• Zhang W, Kornblau S M, Kobayashi T, Gambel A, Claxton D, Deisseroth A B. High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia. Clin Cancer Res 1995; 1: 1051–1057
   PubMed Web of Science ®Google Scholar
• Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 2001; 12: 375–391
   PubMed Web of Science ®Google Scholar
• Vinante F, Rigo A, Vincenzi C, Ricetti M M, Marrocchella R, Chilosi M, et al. IL-8 mRNA expression and IL-8 production by acute myeloid leukemia cells. Leukemia 1993; 7: 1552–1556
   PubMed Web of Science ®Google Scholar
• Francia di Celle P, Mariani S, Riera L, Stacchini A, Reato G, Foa R. Interleukin-8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion. Blood 1996; 87: 4382–4389
   PubMed Web of Science ®Google Scholar
• Francia di Celle P F, Carbone A, Marchis D, Zhou D, Sozzani S, Zupo S, et al. Cytokine gene expression in B-cell chronic lymphocytic leukemia: evidence of constitutive interleukin-8 (IL-8) mRNA expression and secretion of biologically active IL-8 protein. Blood 1994; 84: 220–228
   PubMed Web of Science ®Google Scholar
• Chiaretti S, Li X, Gentleman R, Vitale A, Vignetti M, Mandelli F, et al. Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. Blood 2004; 103: 2771–2778
   PubMed Web of Science ®Google Scholar
• Park J H, McCusker R H, Vanderhoof J A, Mohammadpour H, Harty R F, MacDonald R G. Secretion of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 by intestinal epithelial (IEC-6) cells: implications for autocrine growth regulation. Endocrinology 1992; 131: 1359–1368
   PubMed Web of Science ®Google Scholar
• Mouhieddine O B, Cazals V, Kuto E, Le Bouc Y, Clement A. Glucocorticoid-induced growth arrest of lung alveolar epithelial cells is associated with increased production of insulin-like growth factor binding protein-2. Endocrinology 1996; 137: 287–295
   PubMed Web of Science ®Google Scholar
• Menouny M, Binoux M, Babajko S. Role of insulin-like growth factor binding protein-2 and its limited proteolysis in neuroblastoma cell proliferation: modulation by transforming growth factor-β and retinoic acid. Endocrinology 1997; 138: 683–690
   PubMed Web of Science ®Google Scholar
• Corkins M R, Vanderhoof J A, Slentz D H, MacDonald R G, Park J H. Growth stimulation by transfection of intestinal epithelial cells with an antisense insulin-like growth factor binding protein-2 construct. Biochem Biophys Res Commun 1995; 211: 707–713
   PubMed Web of Science ®Google Scholar
• Hoflich A, Lahm H, Blum W, Kolb H, Wolf E. Insulin-like growth factor-binding protein-2 inhibits proliferation of human embryonic kidney fibroblasts and of IGF-responsive colon carcinoma cell lines. FEBS Lett 1998; 434: 329–334
   PubMed Web of Science ®Google Scholar
• Inman B A, Harel F, Audet J F, Meyer F, Douville P, Fradet Y, et al. Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival. Eur Urol 2005; 47: 695–702
   PubMed Web of Science ®Google Scholar
• Shariat S F, Lamb D J, Kattan M W, Nguyen C, Kim J, Beck J, et al. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol 2002; 20: 833–841
   PubMed Web of Science ®Google Scholar
• Hoeflich A, Reisinger R, Lahm H, Kiess W, Blum W F, Kolb H J, et al. Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter?. Cancer Res 2001; 61: 8601–8610
   PubMed Web of Science ®Google Scholar
• Douer D, Koeffler H P. Retinoic acid. Inhibition of the clonal growth of human myeloid leukemia cells. J Clin Invest 1982; 69: 277–283
   PubMed Web of Science ®Google Scholar
• Koeffler H P. Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications. Blood 1983; 62: 709–721
   PubMed Web of Science ®Google Scholar
• Ketley N J, Allen P D, Kelsey S M, Newland A C. Modulation of idarubicin-induced apoptosis in human acute myeloid leukemia blasts by all-trans retinoic acid, 1,25(OH)2 vitamin D3, and granulocyte-macrophage colony-stimulating factor. Blood 1997; 90: 4578–4587
   PubMed Web of Science ®Google Scholar
• Ferrero D, Pessano S, Pagliardi G L, Rovera G. Induction of differentiation of human myeloid leukemias: surface changes probed with monoclonal antibodies. Blood 1983; 61: 171–179
   PubMed Web of Science ®Google Scholar
• Schlenk R F, Frohling S, Hartmann F, Fischer J T, Glasmacher A, del Valle F, et al. Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia 2004; 18: 1798–1803
   PubMed Web of Science ®Google Scholar
• Heuser M, Argiropoulos B, Kuchenbauer F, Yung E, Piper J, Fung S, et al. MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. Blood 2007; 110: 1639–1647
   PubMed Web of Science ®Google Scholar
• de Ruijter A J, Kemp S, Kramer G, Meinsma R J, Kaufmann J O, Caron H N, et al. The novel histone deacetylase inhibitor BL1521 inhibits proliferation and induces apoptosis in neuroblastoma cells. Biochem Pharmacol 2004; 68: 1279–1288
   PubMed Web of Science ®Google Scholar
• Alonso S R, Ortiz P, Pollan M, Perez-Gomez B, Sanchez L, Acuna M J, et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol 2004; 164: 193–203
   PubMed Web of Science ®Google Scholar